I. Introduction: The Extrapyramidal System

II. The Pharmacology of Parkinsonism .......... 7
  A. Parkinsonism as a Syndrome ............... 7
  B. Cholinergic and Anticholinergic Mechanisms in Parkinsonism 10
  C. Dopaminergic and Antidopaminergic Mechanisms in Parkinsonism 15
  D. Parkinsonism and Neurotransmitter Balance ............. 29
  E. Modification of the Dopaminergic Approach ............ 36
  F. Vitamin Be, L-Dopa and Parkinsonism ................ 45

III. The Pharmacology of Diseases Closely Related to Parkinsonism 48
  A. L-Dopa: the Relationship between Range of Efficacy and Mechanism of Action 48
  B. Olivopontocerebellar Degeneration ............... 49
  C. Progressive Supranuclear Palsy .................. 52
  D. Parkinsonism Associated with Other Neurologic Involvement 58
  E. Chronic Manganese Intoxication ............... 60
  F. Conclusion ............... 62

IV. The Pharmacology of Tardive Dyskinesias ................ 64
  A. Dopaminergic Mechanisms .................. 64
  B. Cholinergic Influences ............... 68

V. The Pharmacology of Huntington's Chorea ............... 71
  A. Huntington's Chorea: a Disease of Striatal Neurons ..........71
  B. The Relationship of Dopamine to Chorea ............... 73
  C. Rigidity and Akinesia in Huntington's Chorea ............ 79
  D. L-Dopa and Presymptomatic Detection of Huntington's Chorea .. 82
  E. Cholinergic Mechanisms in Huntington's Chorea .......... 83

VI. Pharmacologic and Biochemical Considerations in Other Choreiform States . 87
  A. Acquired Hepatocerebral Degeneration ............ 87
  B. Chorea in Hyperthyroidism .................. 91
  C. Chorea in Other Disorders .................... 94
    1. Systemic Lupus Erythematosus ....................94
    2. Sydenham's Chorea .................... 95
    3. Senile Chorea .................... 96

VII. L-Dopa-Induced Dyskinesias ....................... 98
  A. Clinical Description ....................... 98
  B. Pathophysiology ....................... 102
  C. Therapeutic Approaches ....................... 105

VI Table of Contents

VIII. Hepatolenticular Degeneration and Other Dystonias ............ 106
  A. Hepatolenticular Degeneration ....................106
    1. Manifestations: Neurologic and Non-Neurologic .......... 106
    2. Pathology: Anatomic and Chemical .................... 108
Acknowledgments

Much of this book is based on clinical studies performed by members of the Department of Neurology, Rush-Presbyterian-St. Luke’s Medical Center. Many staff members, residents and medical students participated in this work. I would like to acknowledge the active and often original contributions of FLOYD A. DAVIS, MICHAEL A. ERLICH, JAMES A. GOODWIN, M. M. ILAHI, ROBERT MCKENDALL, STEVEN P. RINGEL, RANDI RUBOVITS, DAVID M. SHENKER, JORDAN D. WAXMAN, WILLIAM J. WEINER, and EARL ZEITLIN. GEORGE W. PAULSON of Ohio State University and ANDRE BARBEAU of the University of Montreal took part in some of these studies and my debt to both of these investigators is significant. Support for this work was generously contributed by the United Parkinson Foundation, Chicago, Illinois, and its president, EDGAR N. GREENEBAUM. Their continued financial assistance is deeply appreciated. Thanks are also due to Mrs. VALERIE MEINEKE for typing and secretarial assistance in preparation of the manuscript, to Dr. RANDI RUBOVITS for assistance in compiling the bibliography and Dr. DONNA BERGEN for assistance in final editing and in compiling the index.